Novo Nordisk A/S (NONOF)

OTCMKTS · Delayed Price · Currency is USD
71.01
-0.24 (-0.34%)
Jun 4, 2025, 12:29 PM EDT
-47.07%
Market Cap 315.80B
Revenue (ttm) 43.92B
Net Income (ttm) 15.16B
Shares Out n/a
EPS (ttm) 3.40
PE Ratio 20.83
Forward PE 17.50
Dividend 1.66 (2.28%)
Ex-Dividend Date Mar 28, 2025
Volume 10,902
Average Volume 99,846
Open 70.00
Previous Close 71.25
Day's Range 70.00 - 73.98
52-Week Range 55.28 - 149.55
Beta 0.21
RSI 57.38
Earnings Date May 7, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]

Sector Healthcare
Founded 1923
Employees 77,349
Stock Exchange OTCMKTS
Ticker Symbol NONOF
Full Company Profile

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK Financial Statements

News

Novo Nordisk faces fierce competition in China’s diabetes drug market

Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent repor...

2 days ago - South China Morning Post

The boomerang era: A slew of former CEOs are suiting up once more to take top roles at their old companies

From Novo Nordisk to UnitedHealth, former chief executives are returning to guide their former organization in times of trouble.

5 days ago - Fortune

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

6 days ago - Investor's Business Daily

Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track

Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track.

6 days ago - WSJ

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

Penny stock Veru Inc. (NASDAQ: VERU) on Wednesday released topline safety results from the Phase 2b QUALITY study of enobosarm 3mg, enobosarm 6mg, or placebo to enhance fat loss and prevent muscle lo...

7 days ago - Benzinga

Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.

7 days ago - The Motley Fool

Final Trade: ASML, XYZ, XLC, NVO

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

7 days ago - CNBC Television

Weight-loss drugs like Ozempic and Wegovy continue to be in high demand—and expensive. Are prices likely to come down soon?

The supply of GLP-1 drugs has been increasing, but they're still expensive for most patients. Here are answers to some questions consumers have.

8 days ago - WSJ

Novo Nordisk’s hunt for boss with Danish values — and US commercial nous

Jørgensen’s ousting unusual for group where CEOs have had smooth transitions after long tenures

9 days ago - Financial Times

Should everyone be taking drugs like Ozempic? Drugs in the GLP-1-category show promise for a growing list of health conditions

GLP-1 drugs for weight loss and treating diabetes show promise for an ever-expanding list of diseases.

9 days ago - WSJ

Final Trade: AAPL, NVO, TLT, X

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

11 days ago - CNBC Television

Mizuho's Jared Holz talks what is next for Novo Nordisk

Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.

11 days ago - CNBC Television

Mizuho's Jared Holz talks what is next for Novo Nordisk

Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.

11 days ago - CNBC

Novo Nordisk's High Risk/Reward Proposition: 129% Rally Or 65% Drop?

Novo Nordisk A/S ( NOVO-B) has entered the 18th and final phase of its long-term Weekly Adhishthana Cycle, marking a potentially transformative period. While the weekly charts point to a possible Nirv...

12 days ago - Benzinga

Novo Nordisk's High Risk/Reward Proposition: 129% Rally Or 65% Drop?

Novo Nordisk A/S (NOVO-B) has entered the 18th and final phase of its long-term Weekly Adhishthana Cycle, marking a potentially transformative period. While the weekly charts point to a possible Nirva...

12 days ago - Benzinga

Novo Nordisk offers Wegovy for $199 for first month to new cash-paying customers

Novo Nordisk said on Thursday it is offering self-paying patients who are new to its weight loss drug Wegovy their first month of medicine for $199 through June 30.

13 days ago - Reuters

New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect

With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptions New, one-time $199 first-m...

13 days ago - PRNewsWire

Focus: Novo Nordisk's former chief makes comeback to steer choice of new CEO

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet."

13 days ago - Reuters

Pressure is mounting on Lund at BP and Novo Nordisk

The Norwegian has become a lightning rod for shareholder criticism as chair of both companies

13 days ago - Financial Times

Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs

Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

13 days ago - CNBC

Novo Nordisk Foundation pledges $57 million to WHO amid US funding gap

The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to expand its tie-up with the United Nations agency for another four years, the ph...

14 days ago - Reuters